Conference
September 13, 2021

The Virtual Reality: Tips for Making the Most of Conference Attendance in 2021 and Beyond

Conference
July 26, 2021

The Virtual Reality: Tips for Making the Most of Conference Attendance in 2021 and Beyond

Author

What will conferences look like for MSLs throughout 2021, 2022, and beyond? And how should MSLs prepare to make the most of the changing reality?

Scientific conferences are an essential tool for any Medical Science Liaison. They offer a convenient and efficient way to engage with KOLs and provide an influx of new data for insight generation. But the nature of these events has changed drastically in the last year. As we look with hope to the post-pandemic future, what can we expect? What will conferences look like for MSLs throughout 2021, 2022, and beyond? And how should MSLs prepare to make the most of the changing reality?

Allow us to make a provocative prediction: The future of conferences is definitively virtual.

While hybrid and in-person events have begun to re-appear on our calendars (including the 9th Annual MSLS Conference!), the pandemic has shown us both the benefits and feasibility of virtual events. And in the long run, there’s just no going back. In fact, 64% of the Top 100 Oncology conferences in 2021 are still planning to be held completely online.

The benefits of virtual conferences are easy to see:

  • Higher attendance from a broader audience without travel or geographic limitations
  • The ability for attendees to participate in more sessions through virtual platforms
  • Expanded access to other attendees before, during, and after the event
  • Lower cost for organizers and attendees

In the end, these benefits all contribute to a potential shift in the way the academic, pharmaceutical, and scientific communities think about conferences. Why wait for one annual conference to disseminate meaningful data? Could a distributed model of more frequent online meetings actually enhance the experience and the resulting impact on patients and providers?

There’s only one way to find out. As experts in remote work and virtual gatherings, we present our tips for successful virtual conference attendance, before, during, and after the event:

1. Plan Ahead:

Virtual attendance means access to much more content—and potentially more KOLs. Review the abstracts as soon as they’re released and set a reasonable schedule for what you can accomplish and who you can connect with during the event. Consider a conference planning tool to help analyze the data and sessions you don’t want to miss.

2. Do Your Research:

An essential MSL skill, even the most dedicated MSL can’t keep up with everything their KOLs are up to in the chaos before a big event. Think outside of the box and look for KOL activity in other digital events (like podcasts and webinars) and in social media. As the start date of the event becomes more difficult to put your finger on, your engagement opportunities now start long before the opening plenary.

Continue reading at The MSL Journal here.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.